C-RLFYCasma Therapeutics
autophagy, targeted degradation, PHLYT
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RLFY
C-RLFYC-RLFYautophagy, targeted degradation, PHLYT
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Summary: This week on The Genetics Podcast, Patrick is joined by Frank Gentile, Chief Executive Officer of Casma Therapeutics. They discuss the role of autophagy in neurodegenerative diseases, Casma’s work on therapies for Gaucher’s disease and Parkinson’s disease, and the challenges and opportunities in rare disease biotech. Show Notes: 0:00 Intro to The Genetics Podcast 00:58 Welcome to Frank 02:00 Origin story for Casma Therapeutics and its therapeutic focus on autophagy 04:51 Diseases in which autophagy is dysregulated 07:46 The link between GBA1 and Parkinson’s, and why so many neurodegenerative diseases exhibit autophagy defects 12:28 Findings from Casma Therapeutics’ preclinical studies and associated mechanisms 16:46 Milestones and design of Casma Therapeutics’ upcoming clinical studies 20:24 Well-characterized cohorts of GDPD patients from natural history studies 21:55 Identifying alternative therapeutic targets involved in autophagy initiation that ar
This week on The Genetics Podcast, Patrick is joined by Frank Gentile, Chief Executive Officer of Casma Therapeutics. They discuss the role of autophagy in neurodegenerative diseases, Casma’s work on therapies for Gaucher’s disease and Parkinson’s disease, and the challenges and opportunities in rare disease biotech. Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Frank 02:06 Origin story for Casma Therapeutics and its therapeutic focus on autophagy 05:14 Diseases in which autophagy is dysregulated 08:07 The link between GBA1 and Parkinson’s, and why so many neurodegenerative diseases exhibit autophagy defects 13:02 Findings from Casma Therapeutics’ preclinical studies and associated mechanisms 17:26 Milestones and design of Casma Therapeutics’ upcoming clinical studies 21:07 Well-characterized cohorts of GDPD patients from natural history studies 22:45 Identifying alternative therapeutic targets involved in autophagy initiation that are mTOR independent 2
Chankillo Archaeoastronomical Complex Join our newsletter © 2026 World Monuments Fund. Privacy Policy World Monuments Fund ® and World Monuments Watch ® are registered service marks. World Monuments Fund logo is a trademark of World Monuments Fund. © 2024 World Monuments Fund. Registered 501(c)(3). EIN: 13-2571900
HOSPITAL DE CASMA REALIZA SESIÓN DEMOSTRATIVA DE ALIMENTACIÓN SALUDABLE COMO ESTRATEGIA PARA EVITAR Y CONTROLAR LA HIPERTENSIÓN ARTERIAL Y DIABETES EN LA POBLACIÓN. A través de la Estrategia Sanitaria de Daños no Transmisibles y el Programa de Diabetes e Hipertensión Arterial (HTA) del Hospital de Apoyo San Ignacio de Casma, se realizó la sesión demostrativa de alimentación saludable dirigida a los pacientes del centro de salud que padecen de estas enfermedades. Según la Lic. Melanie Pérez Sánchez, responsable del programa, el objetivo fue concientizar a la población sobre la importancia del c
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
GlassBuild America 2026 | GlassBuild America Skip to main content Show Info Show Info Attend Registration & Hotels Why Attend? Schedule Plan Your Trip Hotel Accommodations Travel & Transportation International Visitors News & Insights Event News Official Magazines 2025 Photo Highlights About About GlassBuild America Show FAQs Future Dates Marketing Affiliations Contact Us Education & Events Education & Events Education at GlassBuild GlassBuild Main Stage GlassBuild Skills Challenge Women in Glass Speakers More Events NEW! Opening Celebration Party (Allegiant Stadium) Award … Products Product Showcase Innovation Lounge Exhibit Why Exhibit? 2026 Exhibitor Application Details For Confirmed Exhibitors (Login Required) Sponsors Become a Sponsor Sponsor the GlassBuild Opening Celebration Party Thanks to Our Sponsors Show Info Show Info Attend Registration & Hotels Why Attend? Schedule Plan Your Trip Hotel Accommodations Travel & Transportation International Visitors News & Insights Event News Official Magazines 2025 Photo Highlights About A … n Glass Speakers More Events NEW! Opening Celebration Party (Allegiant Stadium) Award Ceremonies GlassBuild Podcast Studio Exhibitors & Products Exhibitors & Products Exhibitors Exhibitor List Interactive Floorplan Exhibitor Products Product Showcase Innovation Lounge Exhibit Why Exhibit? 2026 Exhibitor Application Details For Confirmed Exhibitors (Login Required) Sponsors Become a Sponsor Sponsor the GlassBuild Opening Celebration Party Thanks to Our Sponsors GlassBu … how as the… READ MORE GlassBuild America Receives Trade Show Executive Gold 100 Award GlassBuild America: The Glass, Window & Door Expo received a Trade Show Executive (TSE) Gold 100 Award,… READ MORE Hurricane Impact Demo Presented by Intertek This popular and must-see demonstration simulates how innovations in fenestration products react to the effects of… READ MORE Join Us at the GlassBuild-in-the-Fast-Lane After Party Attend the GlassBuild-in-the-Fast-La ne After Part
InterGrowth InterGrowth Related by string. * * ACG InterGrowth * Related by context. Frequent words. (Click for all words.) 63 HSMAI Affordable Meetings 61 MED Week 61 EXHIBITOR 61 Datamatix 60 EXHIBITOR# 60 Mid Atlantic Bio 60 Realcomm 59 Dscoop 58 Hosted Buyers 58 Networking Reception 58 Annual NAMIC 58 SEBIO 58 AIBTM 58 PACK EXPO 58 Silver Sponsor 57 Digital Signage Expo 57 OSP EXPO 57 ASNP 57 BioPharm America 57 Parallels Summit 56 Exhibitor Profiles 56 ISPCON 56 WETEX 56 MEFTEC 56 CASMA 56 SIIM 56 DealFlow Media 56 IHRIM 56 ALTM 56 ICR XChange 56 PLMA 56 CONNECTIONS TM 56 GRAPH EXPO 56 AD
%PDF-1.6 %���� 1944 0 obj > endobj 1965 0 obj >/Filter/FlateDecode/ID[ ]/Index[1944 32]/Info 1943 0 R/Length 105/Prev 172878/Root 1945 0 R/Size 1976/Type/XRef/W[1 3 1]>>stream h�bbd```b``z"g��X�2 ����U`�����M �=L&�Ev��.��50���"����$5 ��k6-H�����������@�g��� ��M endstream endobj startxref 0 %%EOF 1975 0 obj >stream h�b```�� � �@����9:�?��g� ��$�}� �>� pEH@����r�� �E���Y�MdK`[öL$�dR� Q�ٟ ���Vi�t�q� L��@��:@�� S endstream endobj 1945 0 obj >/Metadata 27 0 R/PageLayout/OneColumn/Pages 1942 0 R/StructTreeRoot 31 0 R/Type/Catalog>> endobj … dc055e8-3421-4143-a5ef-8065c47a5d96 uuid:c8140bad-8901-4ff3-90d3-98bdb0146dac 3 application/pdf Gwynn Breckenridge Adobe PDF Library 21.5.92 D:20210901212715 endstream endobj 28 0 obj >stream h�2�41R0P���w�/�+Q0���L)�6�41 )�Ic0i "c�C* R��S��� �L� endstream endobj 29 0 obj >stream h�l�= �0�ῒ�v�&��T�� T����#W�)�o*"n�px�(�!�,�I�OH���:Ǧ���9B���v� �;�ʵ](o�U�CT�$��\�\�ô�� ��*�MX+�6�|�.@L v@b{$'Kh�!��5�?b�� �i4�` �V�&Em0٠�q�ņ4� ,� K ��, �� ڇ���W����%�@=O@ en
Registrations open for 2025 SCGC Screen Composer Summit | Screen Composers Guild of Canada MEMBERSHIP LOG IN --> About What We Do History and People Governance Join Now Networking Find a Composer Events Discuss List Education SCGC Academy Screen Composers Studio Podcast Working with a Composer SCGC Model Contract SCGC Business Tool Kit SCGC Mentorship Program Industry Links Advocacy Canadian Screen Music Awards Advocacy Campaigns SCGC Member Survey 2023 Defining Buyouts Digital Disruption Study Christopher Dedrick Music Fund News/Events Latest News SCGC Events Composer News Cue Notes Spotting … pact24 Public Relations PREVIOUS POST Jennifer Brown receives CASMA award NEXT POST SCGC and SPACQ-AE bring composers together in Montreal POPULAR POSTS Spotting Notes Spotting Notes Winter 2019 SCGC 14 Jan 2019 Recent News & Events New Site Walkthrough SCGC 01 Jun 2022 Events Basic Kontakt – scripting and instrument sound design SCGC 20 Apr 2021 Spotting Notes Spotting Notes Spring 2022 SCGC 14 Apr 2022 Composer News Interview with CSA Nominee Lawr … io SCGC Leadership Code of Conduct Mentorship Program Christopher Dedrick Music Fund Membership Benefits Join Find a Composer Working with a Composer Model Contract Defining Buyouts Industry Links Digital Disruption Study Baseline Study Gender Advocacy SCGC Endorsed Rates IMDBPro Discount News & Events Advocacy Mentorship Program Screen Composers Podcast Composer News SCGC Events Contact Us With thanks to Ontario Creates THE SCREEN COMPOSERS GUILD OF CANADA GRATEFULLY AC … CANADA GRATEFULLY ACKNOWLEDGES THE SOCAN FOUNDATION FOR SUBSTANTIAL OPERATIONAL GRANT FUNDING. © COPYRIGHT 2021 SCREEN COMPOSERS GUILD OF CANADA. ALL RIGHTS RESERVED. WEBSITE MADE BY FRAME Privacy Policy Name: Type: View Crop Image Crop Continue Without Cropping Close this module Log In to Access Your Account Username or Email Address * Password * Lost your password? Remember Me Authenticate to login TOTP Authentication Open your authentication app and type the 6 digit p
Conferences | College of Education - The University of Iowa Skip to main content The University of Iowa College of Education Top links Apply Search Submit Search Search Site Main Navigation Academics Undergraduate Programs Majors Minors Undergraduate to Graduate Programs (U2G) Undergraduate Certificates and Teaching Endorsements UI REACH Graduate Programs Masters Doctoral (EdD, PhD) Graduate Certificates Explore by Area of Study Search All Programs Areas of Study Counseling and Mental Health Clinical Mental Health Counseling Clinical Rehabilitation Counseling Counseling and Behavioral Health S … arch Centers and Initiatives Grants Grants and Research Services Center Faculty Grant Funding Student Grant Funding Student Experience Be a Teacher Academic Advising Baker Teacher Leader Center Education Technology Center Graduate Student Resources UI REACH UI WILD Continuing Education Certificates and Endorsements Professional Development Online Programs Cost and Aid Scholarships About Administration Department of Counselor Education Department of Educational Policy and Lead
Autophagy: Mechanisms to Therapy | Keystone Symposia Sign-in/Account Create Account Cart --> Conferences Digital Pass for Institutions On Demand For Purchase Conference List How to Register Invitation Letter Submit an Abstract Poster Display Guidelines View Abstracts Cancellations and Transfers Submit a Conference Concept Why Participate? Past Conferences Financial Aid Student Discounts Scholarships Global Health Awards Early-Career Travel Awards Financial Aid Portal Login Support Us Current Supporters Media Support Support a Meeting Support in Other Ways Program Enrichment C … utions On Demand For Purchase Conference List How to Register Invitation Letter Submit an Abstract Poster Display Guidelines View Abstracts Cancellations and Transfers Submit a Conference Concept Why Participate? Past Conferences Financial Aid Student Discounts Scholarships Global Health Awards Early-Career Travel Awards Financial Aid Portal Login Support Us Current Supporters Media Support Support a Meeting Support in Other Ways Program Enrichment Career Accelerators Health … ; In Person On Demand Meeting Summary Why Keystone Symposia? Submit an Abstract Abstract Submission Closed Meeting Deadlines Scholarships/Awards Program Pricing & Registration Spread the Word Lodging Travel Information Venue Information × - Feb 02–05, 2026 | Keystone Resort, Keystone, CO, United States Scientific Organizers: Anne Simonsen , Sharon A. Tooze , and Dan Baird Anne Simonsen, PhD University of Oslo Sharon A. Tooze, PhD Francis Crick … y: Genentech, Inc. Merck & Co., Inc. Important Deadlines Early Registration Deadline: December 4, 2025 Scholarship Deadline: November 6, 2025 Global Health Award Deadline: Deadlines not yet available for this meeting. Short Talk Abstract Deadline: December 4, 2025 Poster Abstract Deadline: January 13, 2026 Meeting Summary # Biochemistry, Structural and Cellular Mark your calendar for the next Autophagy conference, ' Autophagy in Health and Disease: From Mechanisms t … REED TO COVER THE EXPENSES OF THEIR EMPLOYEES WHO ARE SPEAKING AT THIS MEETING: GRANT RECOGNITION: KEYSTONE SYMPOSIA THANKS OUR GIFT-IN-KIND MEDIA SPONSORS Subscribe for Updates Conferences Conferences Conference List How to Register Invitation Letter Submit an Abstract Poster Display Guidelines View Abstracts Cancellations and Transfers S
Casma Therapeutics to Present at 2021 Stifel Virtual Healthcare Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opini … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Casma Therapeutics to Present at 2021 Stifel Virtual Healthcare Conference November 10, 2021 | 1 min read Twitter LinkedIn Facebook Email Print Casma Therapeutics, Inc., a biotechnology company harnessing the power of autophagy to design innovative new medicines, announced that Chief Executive Officer, Keith Di … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Casma Therapeutics Appoints Frank Gentile, Ph.D., as CEO | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architecture and Construction Residential Real Esta
Casma Therapeutics Announces Publication in Science --> Accessibility: Skip TopNav Casma Therapeutics Announces Publication in Science Advances Highlighting Novel Mechanism Related to TFEB Activation and Lysosomal Biology Study demonstrates GABARAP-dependent TFEB activation plays a key role in regulating lysosomal homeostasis October 04, 2021 08:00 ET | Source: Casma Therapeutics, Inc. Casma Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Casma Therapeutics , Inc., a biotechnology company harnessing the process of autophagy to design new medicines, today announced
Casma Therapeutics Company Overview, Contact Details & Competitors | LeadIQ Learn more at LeadIQ.com Start free Insights Similar companies Tech Stack Media & News Email Format FAQ Insights Innovative Therapeutics Casma Therapeutics is focused on developing first-in-class therapies targeting cellular degradation systems for neurodegeneration, oncology, inflammation, and metabolic disorders, presenting opportunities for collaboration with healthcare providers and pharmaceutical companies seeking novel treatment options. Funding Momentum With recent investments totaling over $58 million f … . has been awarded approximately $7.6 million in funding across two competitive grant programs from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support Casma's lead program, CSM-101. Mar 11, 2026 | www.bioworld.com Casma Therapeutics, Inc is developing CSM-101 as a potential disease-modifying oral treatment for people with Parkinson's disease and Gaucher disease. Casma Therapeutics said it will develop CSM-101 as a potential disease-modifying
Exclusive: After cutting most staff, Casma eyes path to clinic with its first autophagy-boosting drug | Frank Gentile | 41 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continu
Board and Staff : About Us : Usher 1F Collaborative Skip to main content search About Us Board and Staff Resources and Partnerships Financials Contact Us The Research Usher 1F Research Network Areas of Focus RUSH1F - Usher 1F Natural History Study Usher 1F Stories News & Events Usher 1F Collaborative News Newsletters Relevant Research in the News Event Calendar Take Action DONATE Become a Luminary Donor Laurie and Gary Shapiro Memorial Fund Volunteer Join our mailing list Fundraising Toolkit DONATE Seeing Forward SEEING FORWARD Seeing Forward brochure USHER 1F CANADA Usher 1F Collaborative … dar Take Action DONATE Become a Luminary Donor Laurie and Gary Shapiro Memorial Fund Volunteer Join our mailing list Fundraising Toolkit DONATE Seeing Forward SEEING FORWARD Seeing Forward brochure USHER 1F CANADA Usher 1F Collaborative Canada Illuminating the Future Catch The Ace Usher 1F Collaborative Canada Board Usher 1F Canada Stories Donate - Canada Contact us Privacy Policy Privacy Policy What Information Do We Collect? When you visit our website you may provide us wit … ancial statement of the charitable organization disclosing assets, liabilities, fund balances, revenue and expenses for the preceding fiscal year will be provided to any person upon request. © Usher 1F Collaborative 2026 Crafted by Firespring © Usher 1F Collaborative 2026 Crafted by Firespring About Us Board and Staff Resources and Partnerships Financials Contact Us The Research Usher 1F Research Network Areas of Focus RUSH1F - Usher 1F Natural History Study Usher 1 … dar Take Action DONATE Become a Luminary Donor Laurie and Gary Shapiro Memorial Fund Volunteer Join our mailing list Fundraising Toolkit DONATE Seeing Forward SEEING FORWARD Seeing Forward brochure USHER 1F CANADA Usher 1F Collaborative Canada Illuminating the Future Catch The Ace Usher 1F Collaborative Canada Board Usher 1F Canada Stories Donate - Canada Contact us Get Involved Donate Now Upcoming Events Get Our Newsletter MENU CLOSE Residents of Ontario, Canada, purchase a
News & media - Page 4 of 4 - Casma Therapeutics News & media - Page 4 of 4 - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home News & media News & media Filter by: Year Select One 2026 2025 2024 2023 2022 2021 2020 2019 2018 Type Select One News Publication Go News Investors and Media, George Washington | May 3, 2018 Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Casma Therapeutics Co-Founder Reports Health Benefits of Increased Autophagy in Mammals in Nature Publication - Casma Therapeutics Casma Therapeutics Co-Founder Reports Health Benefits of Increased Autophagy in Mammals in Nature Publication - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics Co-Founder Reports Health Benef... Casma Therapeutics Co-Founder Reports Health Benefits of Increased Autopha … bstantial health benefits. It’s an exciting therapeutic target.” The 2016 Nobel Prize for Physiology or Medicine was awarded for the discovery of the key mechanisms of autophagy. Dr. Levine and colleagues first discovered BECN1 and described its role in mammalian autophagy 20 years ago. About Casma Therapeutics Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approac … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Andrea Ballabio - Human Technopole Skip to content Andrea Ballabio Search for: EN / IT HOME About us Our Mission Governance News & outreach Join us PhD & Postdoc Opportunities People Research Groups ALL GROUPS Genomics Bienko Group Calviello Group Carninci Group Domínguez Conde Group Giustacchini Group Glastonbury Group Legnini Group Soranzo Group Soskic Group Neurogenomics Davila-Velderrain Group Harschnitz Group Kalebic Group Taverna Group Testa Group Structural biology Casañal Group Coscia Group Erdmann Group Vannini Group Computational biology Iorio Group Jug Group Pin … M.D. degree in 1981 at the University of Naples, Italy, where he completed his residency in Pediatrics. He was then post-doctoral fellow at the Institute of Genetics and Biophysics in Naples and at Guy’s hospital in London UK. In 1989 he moved to the USA where he was Assistant and then Associate Professor and Co-director of the Human Genome Center at the Department of Molecular and Human Genetics of Baylor College of Medicine in Houston, Texas. In 1994 he became the founding … aylor College of Medicine in Houston, Texas. He won 3 times the Advanced 5 year-grant Grant of the European Research Council (ERC). In 2016 he won the Louis-Jeantet prize for Medicine. Dr. Ballabio is also an Advisory Board Member of INGM Milan, IGBMC Strasbourg, Human Technopole Milan, and VIMM Padua. He is Co-Founder of CASMA Therapeutics and serves as scientific advisor in Next Generation Diagnostics and Avilar Therapeutics. He has been an EMBO member since 1998 and was a … iological Sciences from the University of Camerino. He then won the Feltrinelli Prize in 2021 and subsequently became member of the Accademia dei Lincei in Rome. Contacts [email protected] --> How to reach us Press room Newsletter --> Transparent Administration Tenders Expressions of interest Whistleblowing HT Intranet Privacy Cookie Policy Social Media Policy Manage Cookies Fondazione Human Technopole - Viale Rita Levi-Montalcini, 1 - Area MIND - 20157 Milano Italy - C.
Casma Therapeutics Announces Partnership with Fondazione Telethon, Founder of the Telethon Institute of Genetics and Medicine (TIGEM) - Casma Therapeutics Casma Therapeutics Announces Partnership with Fondazione Telethon, Founder of the Telethon Institute of Genetics and Medicine (TIGEM) - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics Announces Partnership with Fond... Casma Therapeutics Announc … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Casma Therapeutics Announces Publication in Science Advances Highlighting Novel Mechanism Related to TFEB Activation and Lysosomal Biology - Casma Therapeutics Casma Therapeutics Announces Publication in Science Advances Highlighting Novel Mechanism Related to TFEB Activation and Lysosomal Biology - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics Announces Publication in Scienc... Casma Therapeuti … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Andrea Ballabio, M.D., awarded Beth Levine, M.D. Prize in Autophagy Research from UT Southwestern: Newsroom - UT Southwestern, Dallas, Texas Skip to Main Optimized for Internet Explorer 11 As of January 8, 2016, the standard browser for UT Southwestern will be IE 11 . To ensure the best web experience, please upgrade to the latest standard browser for your computer. Upgrade your browser Faculty Resources Employee Resources Back to UT Southwestern Home UT Southwestern Home Back to UT Southwestern Home UT Southwestern Sites UT Southwestern Home Home - EDU Research Education & Tra … s Media Relations Get Our News Andrea Ballabio, M.D., awarded Beth Levine, M.D. Prize in Autophagy Research from UT Southwestern Published on: June 16, 2025 • By: Newsroom Share Share on Facebook Share on Twitter Share on LinkedIn Email this page Print this page DALLAS – June 16, 2025 – Italian medical geneticist Andrea Ballabio, M.D., an internationally recognized scientist who has devoted his career to elucidating the mechanisms underlying … ng genetic diseases, has been named the recipient of the 2025 Beth Levine, M.D. Prize in Autophagy Research from UT Southwestern Medical Center. The $20,000 prize and lecture, established in honor of the late Dr. Levine, who was Director of UT Southwestern’s Center for Autophagy Research, is awarded biennially to exceptional scientists who have made significant contributions to the field of autophagy, a highly regulated process by which cells break down and re … bio, M.D. Andrea Ballabio, M.D., is the recipient of the 2025 Beth Levine, M.D. Prize in Autophagy Research. Dr. Ballabio is the founder and former director of the Telethon Institute of Genetics and Medicine (TIGEM) and Professor of Medical Genetics at the University of Naples “Federico II.” He is also a Visiting Professor in the Department of Molecular and Human Genetics at Baylor College of Medicine in Houston and co-founder and scientific adviser of Casma Thera … ncer,” Dr. Ballabio said. “I am truly honored to receive this prize dedicated to Beth, an amazing scientist and a wonderful colleague.” Dr. Ballabio received his medical degree from the University of Naples “Federico II,” where he completed a residency in pediatrics. He received postdoctoral training at several
Casma Therapeutics Announces new Nature Publication - "Structure of the lysosomal mTORC1–TFEB–Rag–Ragulator megacomplex" - Casma Therapeutics Casma Therapeutics Announces new Nature Publication - "Structure of the lysosomal mTORC1–TFEB–Rag–Ragulator megacomplex" - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics Announces new Nature Publicatio... Casma Therapeutics Announces new … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Collaboration Deals in Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Network FA … The Jackson Laboratory The Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center The Native Antigen Company The New York Stem Cell Foundation The Parker Institute For Cancer Immunotherapy Theragen Theragent TheraPanacea Theriva Biologics Thermo Fisher Scientific ThinkCyte ThirdEye Tianjin CanSino Biotechnology Tianjin University Tiba Biotech TiumBio Tivic Health Systems T Med TMG - Tropical Melhoramento e Genética Today TCI Tolo Biotech Tome … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … nology Related Reports Biotechnology Market Report by Product Type, Technology, Application, and Region 2026-2034  Report 138 Pages April 2026 Global From €3609 EUR $3,999 USD £3,129 GBP Biotechnology Market in the US 2025-2029  Report 170 Pages January 2025 United States From €2256 EUR $2,500 USD £1,956 GBP North America Biotechnology Market Report by Product Type, Technology, Application, Countries and Company Analysis 2025-2033  Report 200 Pages Sep … on Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
Casma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s Disease - Casma Therapeutics Casma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s Disease - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics Receives MJFF Support to Advanc... Casma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s Disease March 10, 20 … t has been awarded approximately $7.6 million in funding across two competitive grant programs from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The non-dilutive funding supports a fully integrated preclinical development strategy for Casma’s lead program, CSM-101, enabling the company to generate new TRPML1 biomarker and IND-enabling data required to advance into first-in-human clinical studies. Casma’s lead molecule, CSM-101, is a highly differentiated, or … preclinical development for CSM-101. A $2.1 million Targets to Therapies (T2T) grant supports continued validation of TRPML1 biology and the development of translational biomarkers to assess lysosomal activation and inform early clinical decision-making, including dose selection and study design. A $5.5 million Therapeutics Pipeline Program (TPP) grant supports IND-enabling studies required to advance CSM-101 into first-in-human clinical trials. Through its Targets to Therap … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Cell Bio 2026 - An ASCB|EMBO Meeting | ASCB Skip to content Menu Meetings & Events Events Calendar Annual Meeting (Cell Bio) Cell Bio 2026 Cell Bio 2025 Past Annual Meetings Future Cell Bio Meetings On-Demand Videos Sponsorship Publications The Post ASCB Journals Molecular Biology of the Cell (MBoC) CBE–Life Sciences Education (LSE) ASCB Policy on Research Misconduct by Authors ASBC Newsletter Advertise & Media Kit Career Development ASCB Connect Job Board/Career Portal Career Posts & Videos Speaker Referral Lists Career Mentoring & Training Programs Biotech Course AS … eer Mentoring & Training Programs Biotech Course ASCB MOSAIC Program (AMP) Grant Writing Training (FRED) Teaching Virtual Teaching Resources Grants & Awards Grants Individual Honorific Awards Policy & Outreach Advocacy & Policy Advocacy Toolkit White Papers & Position Papers Letters & Official Policy Comments Science Outreach Science Outreach Blogs ASCB Communication Toolkits The Cell Image Library Coalition for the Life Sciences (CLS) Declaratio … eer Mentoring & Training Programs Biotech Course ASCB MOSAIC Program (AMP) Grant Writing Training (FRED) Teaching Virtual Teaching Resources Grants & Awards Grants Individual Honorific Awards Policy & Outreach Advocacy & Policy Advocacy Toolkit White Papers & Position Papers Letters & Official Policy Comments Science Outreach Science Outreach Blogs ASCB Communication Toolkits The Cell Image Library Coalition for the Life Sciences (CLS) Declaratio … Opportunities Registration Back to ASCB Home Extended Talk and Poster Abstract Deadline: August 4, 2026 Learn More Join us in San Diego! When: December 12 – 15, 2026 Where: San Diego Convention Center, San Diego, CA Start planning now to join us for Cell Bio 2026, the joint meeting of ASCB and EMBO, where the cell biology community gathers to share science, support one another, and spark new ideas. It's a space to connect with colleagues, celebrate discoveries, and grow toge … your abstracts now. Start preparing your abstract now! Talk & Early Poster Deadline: June 9 Extended Talk & Poster Deadline: August 4 (rates increase after this date) Final Talk & Poster Deadline: September 14 Play Video Exhibit at Cell Bio: Where Science Meets Opportunity Exhibit Hall Dates: December 12-15 Showcase your innovations
Scientist II (Biochemistry) H1B Visa Salary & Sponsorship Data | H1BTrends H1BTrends H1B PERM Reports Green Card Calculator NEW H1B Lottery Odds Calculator (FY 2027) Immigration Updates Loading job title data... Analyzing H1B applications across companies Fetching applications Calculating statistics Preparing insights H1BTrends Search 3M+ H1B LCA and PERM labor certification applications from the U.S. Dept. of Labor. Find H1B sponsoring companies, compare salaries by job title and city, check approval rates, and explore employment-based green card data. Data reflects the most recent five f
Cerro Sechín Join our newsletter © 2026 World Monuments Fund. Privacy Policy World Monuments Fund ® and World Monuments Watch ® are registered service marks. World Monuments Fund logo is a trademark of World Monuments Fund. © 2024 World Monuments Fund. Registered 501(c)(3). EIN: 13-2571900
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Careers & culture - Casma Therapeutics Careers & culture - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Careers & culture Become a Casmaniac Explore the frontier of autophagy OUR CULTURE Fun times, rigorous science Together, we are a diverse and inclusive team at the forefront of autophagy research. We believe that scientists should be creative and share data both freely and selflessly. Our work is challenging, but we are committed to … conditions related to pregnancy, or genetics. Open positions Become a Casmaniac Apply Now! Job opportunities About Casma Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery focuses on larger and more … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
| Screen Composers Guild of Canada MEMBERSHIP LOG IN --> About What We Do History and People Governance Join Now Networking Find a Composer Events Discuss List Education SCGC Academy Screen Composers Studio Podcast Working with a Composer SCGC Model Contract SCGC Business Tool Kit SCGC Mentorship Program Industry Links Advocacy Canadian Screen Music Awards Advocacy Campaigns SCGC Member Survey 2023 Defining Buyouts Digital Disruption Study Christopher Dedrick Music Fund News/Events Latest News SCGC Events Composer News Cue Notes Spotting Notes Contact MEMBERSHIP LOG IN Canadian Screen Music Aw … ment. We are also open to customizing a package for you and can prepare a proposal within your budget. Product donation towards our raffle is also welcome and we can modify a package to include the value of the product. Receive a 10% off EARLY BIRD incentive for sponsors who sign on by April 30th! Founded in 1980, the Screen Composers Guild of Canada (SCGC) is a national association of professional music composers and producers for film, television and media. Our organi … io SCGC Leadership Code of Conduct Mentorship Program Christopher Dedrick Music Fund Membership Benefits Join Find a Composer Working with a Composer Model Contract Defining Buyouts Industry Links Digital Disruption Study Baseline Study Gender Advocacy SCGC Endorsed Rates IMDBPro Discount News & Events Advocacy Mentorship Program Screen Composers Podcast Composer News SCGC Events Contact Us With thanks to Ontario Creates THE SCREEN COMPOSERS GUILD OF CANADA GRATEFULLY AC … CANADA GRATEFULLY ACKNOWLEDGES THE SOCAN FOUNDATION FOR SUBSTANTIAL OPERATIONAL GRANT FUNDING. © COPYRIGHT 2021 SCREEN COMPOSERS GUILD OF CANADA. ALL RIGHTS RESERVED. WEBSITE MADE BY FRAME Privacy Policy Name: Type: View Crop Image Crop Continue Without Cropping Close this module Log In to Access Your Account Username or Email Address * Password * Lost your password? Remember Me Authenticate to login TOTP Authentication Open your authentication app and type the 6 digit p
CASMA: The Canadian Screen Music Awards – From the SCGC About the CASMAs Enter Now Previous Winners 2025 Winners 2024 Winners 2023 Winners 2022 Winners Sponsorship Main SCGC Site SEPTEMBER 14, 2026 Celebrating the best in Canadian screen composing Now in its fifth year, the Canadian Screen Music Awards (CASMA) is an annual celebration of composer’s excellence in scoring original music for the screen. Launched and administered by Screen Composers Guild of Canada , these awards are open to all Canadian and permanent resident composers with winners chosen by the SCGC’s roster of judges. The CASMA … THE DATE September 14, 2026 El Mocambo, Toronto 121 days 20 hours 19 minutes 45 Award categories There are 13 categories under award consideration in 2026 covering film, TV, interactive and theme together with industry award and rising talent awards. For full category definitions and eligibility please see program award definitions below. Film Best Original Score for a Narrative Feature Film Best Original Score for a Documentary Feature Film Best Original Score for a Short Fi … ain Title Theme Music Best Original Song Industry The SCGC Lifetime Achievement Award Rising Talent The SCGC Rising Talent Award is awarded by voting SCGC members NOTE : Productions whose primary purpose is the advertisement or promotion of a company, product or service are ineligible for the SCGC awards at this time. If you are unsure about your eligibility or where your production fits within these categories, please ask us at [email protected] Submissions SCGC memb … [email protected] Submissions SCGC members and non-members and invited to submit entries for the CASMAs or SCGC Rising Talent Awards. These are the first to be juried and awarded by fellow screen composers in Canada with prizes awarded in Toronto on September 14, 2026. CASMA Submission Submissions are now closed for 2026. Rising Talent Submission Submissions are now closed for 2026. SEE PREVIOUS WINNERS CASMA 2022 Winners CASMA 2023 Winners CASMA 2024 Winners CASMA 2025 … available and are also open to customizing a package for you and can prepare a proposal within your budget. Product donation towards our raffle is also welcome and we can modify a package to include the value of the product Learn More SPONSOR THE CASMAS Join our celebration of Canadian composers and reach your customers directly The Screen Compo
Careers & culture - Casma Therapeutics Careers & culture - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Careers & culture Become a Casmaniac Explore the frontier of autophagy OUR CULTURE Fun times, rigorous science Together, we are a diverse and inclusive team at the forefront of autophagy research. We believe that scientists should be creative and share data both freely and selflessly. Our work is challenging, but we are committed to … conditions related to pregnancy, or genetics. Open positions Become a Casmaniac Apply Now! Job opportunities About Casma Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery focuses on larger and more … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Press Releases - Arbor Biotechnologies™ Skip Navigation Toggle Navigation Search: Search Submit Who We Are We Are Arbor ® Our Story Leadership Founders Board of Directors Investors Partnerships What We Do Next-Gen Gene Editing A Diversified Editing Toolbox Arbor ® Publications & Presentations Pipeline Our Pipeline Areas of Focus Clinical Trial Inside Arbor ® The Faces of Arbor ® Our Values Diversity, Equity & Inclusion Community Benefits & Perks Careers Stay Updated Press Releases Social Media Get In Touch Press Releases Press Releases 2026 2025 2024 2023 2022 2021 2020 2019 201 … will showcase Arbor’s expertise in Read More Oct 29, 2025 Samsung Life Science Fund Invests in Arbor Biotechnologies to Develop Next-Generation Genetic Medicines INCHEON, Korea – October 30, 2025 – Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, today announced an equity investment in Arbor Biotechnologies, Inc., a leading Read More Oct 6, 2025 Chies … ic Read More Dec 19, 2024 Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1 CAMBRIDGE, MA – December 19, 2024 – Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Read More Oct 22, 2024 Arbor Biotechnologies
Collaboration Deals in Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Network FA … The Jackson Laboratory The Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center The Native Antigen Company The New York Stem Cell Foundation The Parker Institute For Cancer Immunotherapy Theragen Theragent TheraPanacea Theriva Biologics Thermo Fisher Scientific ThinkCyte ThirdEye Tianjin CanSino Biotechnology Tianjin University Tiba Biotech TiumBio Tivic Health Systems T Med TMG - Tropical Melhoramento e Genética Today TCI Tolo Biotech Tome … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … nology Related Reports Biotechnology Market Report by Product Type, Technology, Application, and Region 2026-2034  Report 138 Pages April 2026 Global From €3609 EUR $3,999 USD £3,129 GBP Biotechnology Market in the US 2025-2029  Report 170 Pages January 2025 United States From €2256 EUR $2,500 USD £1,956 GBP North America Biotechnology Market Report by Product Type, Technology, Application, Countries and Company Analysis 2025-2033  Report 200 Pages Sep … on Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cance … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors November 17, 2020 | 3 min read Twitter LinkedIn Facebook Email Print Casma Therapeutics , Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease June 5, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction … l benefits for patients." Casma plans to file an Investigational New Drug (IND) application with the US FDA for CSM-101 in the first half of 2026. About TRPML1 TRPML1 is a lysosomal ion channel that regulates critical aspects of lysosomal function, including lysosomal pH and the clearance of cellular waste. Dysfunction of TRPML1 leads to impaired degradation and accumulation of toxic substrates, contributing to the pathology of neurodegenerative and lysosomal storage diseases … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Casma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Casma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s Disease March 10, 2026 | 5 min read Twitter LinkedIn Facebook Email Print Funding supports IND-enabling activities for Casma’s CSM-101, a first-in-class TRPML1 agonist targeting lysosomal dysfunction in genetically drive … t has been awarded approximately $7.6 million in funding across two competitive grant programs from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The non-dilutive funding supports a fully integrated preclinical development strategy for Casma’s lead program, CSM-101, enabling the company to generate new TRPML1 biomarker and IND-enabling data required to advance into first-in-human clinical studies. Casma’s lead molecule, CSM-101, is a highly differentiated, or … preclinical development for CSM-101. A $2.1 million Targets to Therapies (T2T) grant supports continued validation of TRPML1 biology and the development of translational biomarkers to assess lysosomal activation and inform early clinical decision-making, including dose selection and study design. A $5.5 million Therapeutics Pipeline Program (TPP) grant supports IND-enabling studies required to advance CSM-101 into first-in-human clinical trials. Through its Targets to Therap … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Casma Therapeutics Announces CEO Transition - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News &am … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Casma Therapeutics Announces CEO Transition January 31, 2023 | 2 min read Twitter LinkedIn Facebook Email Print Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., has stepped down as Chief Ex … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Recon: Lilly, AC Immune Partner on Alzheimer’s Treatment; FDA Rejects Mallinckrodt’s Abuse-Deterrent Opioid | RAPS × Maintenance Notice: You may experience temporary website slowness while maintenance is being performed. Thank you for your patience. We recently upgraded the website! If you run into any issues, please Contact Us . Enjoy exploring the new site! Skip to content Join Login Learn & Develop Books RAPS Library Upcoming Events Courses Learning Portal Online U Certificate Programs Conferences Convergence Euro Convergence Conference Series Conference Group Rates Leade … System ( Forbes ) ( STAT ) Large coalition joins drug lobby in denouncing Trump proposal to import drug prices for Medicare ( Endpoints ) New documents shed light on secretive ElevateBio, next step for former Alexion execs ( STAT ) In Focus: International Samsung BioLogics Vows Improved Management Transparency As Stock Resumes Trade ( SCRIP -$) China’s global reputation shapes its citizens’ reaction to ‘CRISPR babies’ ( STAT ) Scientists Skeptical Abou … rgest ever UK lung cancer screening study ( PharmaTimes ) Revamped Cancer Drugs Fund Means More Positive Recommendations, Says NICE ( Pink Sheet -$) Scottish Medicines Consortium approves Verkazia for severe eye condition in children and adolescents ( Pharmafile ) CHMP Delays Review of Portola's Ondexxya; Who Will Pass Muster? ( Pink Sheet -$) Brexit Delays Key ATMP Guideline Update – EMA Says Perhaps Not So Bad ( Pink Sheet -$) Merck and Instituto Butantan Announce … itico ) Target to pay $3M to resolve Massachusetts Medicaid claim ( AP ) NIH to fund HIV care and prevention research in vulnerable southern US communities ( NIH ) Feds drop insider trading, perjury charges against ex-AMO chief Mazzo ( MassDevice ) McDonald's to curb antibiotic use in its beef supply ( Reuters ) Amgen's Biosimilar IP Win Was Wrong, Hospira Tells Fed. Circ. ( Law360 -$)
Casma Therapeutics Strengthens Leadership Team with Appointment of Chief Operating Officer, Vice President of People & Culture - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Casma Therapeutics Strengthens Leadership Team with Appointment of Chief Operating Officer, Vice President of People & Culture December 12, 2018 | 3 min read Twitter LinkedIn Facebook Email Print Two senior executives who will help lead Casma through its next phase of growth. CAMBRIDGE, M … ing from the Massachusetts Institute of Technology. He completed a postdoctoral fellowship at the Swiss Federal Institute of Technology in Zurich. “I loved working on Casma since its inception at Third Rock and am thrilled to stay with the team as we work to apply a wave of exciting new autophagy research to our drug discovery programs,” Gentile said. “This field has the potential to make a real difference for patients, and Casma is leading the way.” About Casma Therapeutics … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Is it time to target autophagy to treat disease? Skip to Main Content Eli Lilly Donald Trump Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series & Investigations Business Biotech Pharma Health Tech Health Insurance Hospitals Medical Device … cooney_liz @elizabethcooney.bsky.social Tags drug development research STAT+ To submit a correction request, please visit our Contact Us page . Trending Eli Lilly dives into hair loss treatments with investment… Eli Lilly dives into hair loss treatments with investment in AI startup Absci FDA drops enforcement against Whoop after it tweaks blood… FDA drops enforcement against Whoop after it tweaks blood pressure feature Eli Lilly gave extraordinary obesity drug
Casma Therapeutics Announces Publication in Science Advances Highlighting Novel Mechanism Related to TFEB Activation and Lysosomal BiologyStudy demonstrates GABARAP-dependent TFEB activation plays a key role in regulating lysosomal homeostasis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Casma Therapeutics Announces Publication in Science Advances Highlighting Novel Mechanism Related to TFEB Activation and Lysosomal BiologyStudy demonstrates GABARAP-dependent TFEB activation plays a key role in regulating lysosomal homeostasis October 4, 2021 | 2 min read Twitter LinkedIn Facebook Email Print Casma Therapeutics, Inc. … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy to Develop Breakthrough Therapies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developm … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy to Develop Breakthrough Therapies May 3, 2018 | 5 min read Twitter LinkedIn Facebook Email Print Casma Therapeutics, Inc. launched with $58.5 million in Series A funding from Third Rock Ven … protein aggregation to lipid accumulation — that drive disease. The 2016 Nobel Prize for Physiology or Medicine was awarded for the discovery of the key mechanisms of autophagy. Casma’s founders have advanced the understanding of these mechanisms to develop the foundation of potentially powerful disease-modifying therapies to improve the lives of patients. Propelled by a deep understanding of the autophagy process and led by experienced biotech executives, Casma has built a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Casma Therapeutics Announces Partnership with Fondazione Telethon, Founder of the Telethon Institute of Genetics and Medicine (TIGEM) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Casma Therapeutics Announces Partnership with Fondazione Telethon, Founder of the Telethon Institute of Genetics and Medicine (TIGEM) September 11, 2018 | 3 min read Twitter LinkedIn Facebook Email Print Casma Therapeutics, Inc. today announced a research collaboration with Fondazione Teletho … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tiaki Therapeutics Appoints Suzanne Bruhn, PhD, as Chief Executive Officer | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Casma Therapeutics Launches with $58.5 Million - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Casma Therapeutics Launches with $58.5 Million May 3, 2018 | 3 min read | Mark Terry Twitter LinkedIn Facebook Email Print biotechnology concept. chombosan/Getty Images/iStockphoto Casma Therapeutics closed on a Series A round totaling $58.5 million. The company was solely funded … itute of Innovative Research cell biologist Yoshinori Ohsumi, who won the Nobel Prize in Medicine in 2016. Ohsumi is not one of the company’s founders, but four other experts in autophagy are. They are Beth Levine, director of the Center for Autophagy Research at the University of Texas Southwestern Medical Center; Andrea Ballabio, founder and director of the Telethon Institute of Genetics and Medicine of Pozzuoli; James Hurley , Judy C. Webb Chair and professor of biochemist … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Casma cuts staff, plans 2026 clinical trials for Gaucher's and Parkinson's | Endpoints News posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catal
Science - Casma Therapeutics Science - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us The science: autophagy How does it work? The opportunity Our featured experts THE SCIENCE: AUTOPHAGY What is autophagy? Autophagy is a naturally occurring degradation process in cells. Over time certain cellular components become dysfunctional and cause disease. Autophagy monitors these components and if activated will degrade them in a highly selective manner. Au … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Platform & pipeline - Casma Therapeutics Platform & pipeline - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / Platform & pipeline Our approach TRPML1 PHLYT™ Videos Pipeline Platform & pipeline Our approach: Reprogramming autophagy At Casma, we are redefining degradation with our innovative methods. While traditional degradation techniques rely on the ubiquitin-proteasome pathway and often fall short for many crit … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Center for Advanced Studies in Measurement and Assessment (CASMA) | College of Education - The University of Iowa Skip to main content The University of Iowa College of Education Top links Apply Search Submit Search Search Site Main Navigation Academics Undergraduate Programs Majors Minors Undergraduate to Graduate Programs (U2G) Undergraduate Certificates and Teaching Endorsements UI REACH Graduate Programs Masters Doctoral (EdD, PhD) Graduate Certificates Explore by Area of Study Search All Programs Areas of Study Counseling and Mental Health Clinical Mental Health Counseling Clinical Rehabi … arch Centers and Initiatives Grants Grants and Research Services Center Faculty Grant Funding Student Grant Funding Student Experience Be a Teacher Academic Advising Baker Teacher Leader Center Education Technology Center Graduate Student Resources UI REACH UI WILD Continuing Education Certificates and Endorsements Professional Development Online Programs Cost and Aid Scholarships About Administration Department of Counselor Education Department of Educational Policy and Lead
Casma Therapeutics - Reprogramming autophagy to treat disease Casma Therapeutics - Reprogramming autophagy to treat disease Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us CASMA THERAPEUTICS A new approach to targeted degradation Reprogramming autophagy to treat disease The Science: Autophagy What is it? Autophagy is the removal of damaged components within the cell to maintain and improve health. How does it work? Autophagy creates autophagosomes that capture and deg … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
10-K 452 false 467 0001628171 FY http://www.revolutionmedicines.com/20241231#CollaborationRevenueMember http://www.revolutionmedicines.com/20241231#CollaborationRevenueMember http://www.revolutionmedicines.com/20241231#CollaborationRevenueMember P3Y http://www.revolutionmedicines.com/20241231#PresidentAndChiefExecutiveOfficerMember 2026-12-31 http://fasb.org/us-gaap/2024#RevenueFromContractWithCustomerExcludingAssessedTax http://fasb.org/us-gaap/2024#RevenueFromContractWithCustomerExcludingAssessedTax http://fasb.org/us-gaap/2024#RevenueFromContractWithCustomerExcludingAssessedTax 2011 2012 20 … eding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … FDA approval, they could be subject to maximum fair price (MFP) negotiation and application by the Centers for Medicare & Medicaid Services (CMS) under terms of the Inflation Reduction Act of 2022 (the IRA), nine years after launch in the United States. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we a … is generally 20 years from the earliest date of filing a non-provisional patent application, assuming the patent has not been terminally disclaimed over a commonly owned patent or a patent naming a common inventor, or over a patent not commonly owned but that was disqualified as prior art as the result of activities undertaken within the scope of a joint research agreement. In the United States, the term of a patent may also be eligible for patent term adjustment for delays w … rug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek any available patent term extension to any issued patents we may be granted in any jurisdiction where such extensions are available; however, there is no guarantee that the applicable
EP 193: Targeting autophagy to treat neurodegeneration with Frank Gentile of Casma Therapeutics - The Genetics Podcast | Podcast on Spotify
EP 193: Targeting autophagy to treat neurodegeneration with Frank Gentile of Casma Therapeutics - The Genetics Podcast | iHeart Your Library Podcasts News All Episodes EP 193: Targeting autophagy to treat neurodegeneration with Frank Gentile of Casma Therapeutics June 26, 2025 • 38 mins Summary: This week on The Genetics Podcast, Patrick is joined by Frank Gentile, Chief Executive Officer of Casma Therapeutics. They discuss the role of autophagy in neurodegenerative diseases, Casma’s work on therapies for Gaucher’s disease and Parkinson’s disease, and the challenges and
Autophagy: Drugging the yin and yang of the cell --> Advertisement Skip to main content ACS ACS Publications C&EN CAS Jobs Main menu News Topics Newsletter Podcasts Explore Explore Skip Explore section Features Perspectives Interviews ACS News Graphics Chempics Games Newscripts Webinars Whitepapers & E-books Highlights Highlights Skip Highlights section How biochemistry fuels World Cup athletes Meet Jasmine Clark, the self-described ‘mad scientist’ running for the US House Australia’s $1.4 billion PFAS lawsuit could be a global model The road to sustainable rare earths runs through Bra … eaning, is now recognized as a crucial process of self-renewal. After the Nobel Prize was awarded for the discovery of autophagy genes in 2016, several biotech companies launched with plans to develop drugs that either boost or inhibit autophagy to treat a bevy of diseases, including Alzheimer’s and cancer. At first glance, drugging autophagy sounds like a panacea, but each approach carries a risk: boosting autophagy might prevent neurodegeneration at the expense of increasin … ny centered on the cellular process of autophagy, the subject of the 2016 Nobel Prize in Physiology or Medicine , announced just months before. Autophagy literally means self-eating, but the cellular housecleaning it accomplishes is more important than its cannibalistic connotations. Cells build structures called autophagosomes around junk they want to recycle—for example, old or damaged organelles, fat deposits, clumps of poisonous proteins, or even microbial invaders. Once … s for the cell to use and build anew. Related: Yoshinori Ohsumi wins 2016 Nobel Prize in Physiology or Medicine Until 1993, no one knew how this process was controlled. That year, Yoshinori Ohsumi described 15 genes in yeast that were essential for orchestrating autophagy. That work—the basis for his 2016 Nobel Prize—meant researchers could finally study the machinery that made autophagy tick, and perturb it to see what happens when the process is broken. The first connection … bsp; Sources: Companies and academic centers. Getting selective After the Nobel Prize, investors were more receptive to taking meetings with scientists with ideas for autophagy companies. “There is definitely a growing industry excitement around autophagy enhancement,” says Sebastian Aguiar from Apollo Ventures, a venture capital firm focused on
Investors - Casma Therapeutics Investors - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / Investors Why Invest Investors INVESTORS Why invest? The ability to degrade otherwise undruggable intracellular disease causing targets is one of the most exciting new innovations in medicine. Despite remarkable pre-clinical and clinical data showing degradation of soluble disease-causing proteins and peptides; to date, none - have been able … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Investors and Media Archives - Casma Therapeutics Investors and Media Archives - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us news page About Casma Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeos … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Casma Therapeutics Licenses Technology to Advance Autophagy-Based Drug Discovery - Casma Therapeutics Casma Therapeutics Licenses Technology to Advance Autophagy-Based Drug Discovery - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics Licenses Technology to Advance ... Casma Therapeutics Licenses Technology to Advance Autophagy-Based Drug Discovery December 6, 2018 CAMBRIDGE, Mass., Dec. 6, 2018 – C … or a broad range of diseases.The license includes commercial rights to a patent application covering small molecules, and to screening assay technologies developed by Beth Levine, M.D. and Jef De Brabander, Ph.D. to aid discovery of small molecules that can disrupt the interaction between the BECN1 protein and a negative regulator, BCL2. This crucial molecular pathway influences the rate of autophagy, the natural process by which cells break down surplus or dysfunctional prot … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
News & media - Page 2 of 4 - Casma Therapeutics News & media - Page 2 of 4 - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home News & media News & media Filter by: Year Select One 2026 2025 2024 2023 2022 2021 2020 2019 2018 Type Select One News Publication Go News March 26, 2019 Casma Therapeutics Establishes Scientific Advisory Board with Appointments of Leading Autophagy and Neuroscience Researchers CAMBRIDGE, Mass. – March 26, 2019 – … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Casma Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Casma Therapeutics Website: Casma Therapeutics Business Area(s) Therapeutics Description Casma Therapeutics is a preclinical-stage therapeutics company focused on modulating the autophagy pathway to address unmet medical needs and transform the lives of patients. Career Page(s) Careers
Job opportunities - Casma Therapeutics Job opportunities - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Job opportunities About Casma Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The aut … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy to Develop Breakthrough Therapies - Casma Therapeutics Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy to Develop Breakthrough Therapies - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Third Rock Ventures Launches Casma … protein aggregation to lipid accumulation — that drive disease. The 2016 Nobel Prize for Physiology or Medicine was awarded for the discovery of the key mechanisms of autophagy. Casma’s founders have advanced the understanding of these mechanisms to develop the foundation of potentially powerful disease-modifying therapies to improve the lives of patients. Propelled by a deep understanding of the autophagy process and led by experienced biotech executives, Casma has built a … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Careers & culture - Casma Therapeutics Careers & culture - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Careers & culture Become a Casmaniac Explore the frontier of autophagy OUR CULTURE Fun times, rigorous science Together, we are a diverse and inclusive team at the forefront of autophagy research. We believe that scientists should be creative and share data both freely and selflessly. Our work is challenging, but we are committed to … conditions related to pregnancy, or genetics. Open positions Become a Casmaniac Apply Now! Job opportunities About Casma Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery focuses on larger and more … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors - Casma Therapeutics Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics Appoints Nagesh Mahanthappa, Ph... Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors November 17, 2020 CAMBRIDGE, Mass.-November 17, … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Casma Therapeutics Jobs | BioBae Bio Bae Browse Jobs Companies For Employers Home / Companies / Casma Therapeutics C Casma Therapeutics Biotechnology 📍 Cambridge , MA Casma Therapeutics is a biotech company reprogramming autophagy to develop targeted therapies for various diseases by engaging lysosomal and autophagy systems. Visit website → View careers page → Open Positions at Casma Therapeutics 0 positions available No open positions at the moment Check back later for new opportunities! Bio Bae The premier job board for biotech, pharma, and life sciences professionals. For Job Seekers Brows
Jobs at Casma Therapeutics | Consider You are using an outdated browser. Please upgrade your browser to improve your experience and security. Home Sign In Powered by Consider Privacy Terms
Casma Therapeutics has raised more than $150 million since it launched in 2018 to develop drugs that target #autophagy. | Ryan Cross LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Contin
Casma Therapeutics Announces $50 Million Series B Financing - Casma Therapeutics Casma Therapeutics Announces $50 Million Series B Financing - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics Announces $50 Million Series B ... Casma Therapeutics Announces $50 Million Series B Financing September 10, 2020 Funding led by The Column Group Proceeds will be used to advance Casma’s First-in-Class TRPML1 … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
ANDREA BALLABIO RECEIVES THE “BETH LEVINE PRIZE IN AUTOPHAGY RESEARCH” FROM UT SOUTHWESTERN MEDICAL CENTER IN DALLAS — TIGEM Webmail Internal Site Login area Close About About us Discover Tigem Governance Scientific Office Institutional Support Funding and Acknowledgements Research Our Research Research Programs Faculty Facilities Training PhD Training Post-Doc Association Newsroom Seminars Publications Career Opportunities Outreach Outreach Home / Newsroom / News & Events / ANDREA BALLABIO RECEIVES THE “BETH LEVINE PRIZE IN AUTOPHAGY RESEARCH” FROM UT SOUTHWESTERN MEDICAL CENTER IN DALLAS … SOUTHWESTERN MEDICAL CENTER IN DALLAS ANDREA BALLABIO RECEIVES THE “BETH LEVINE PRIZE IN AUTOPHAGY RESEARCH” FROM UT SOUTHWESTERN MEDICAL CENTER IN DALLAS Jun 16, 2025 Named after the recently deceased scientist who discovered the first gene involved in mammalian autophagy, the prize recognizes Ballabio’s contributions to understanding the mechanisms behind cellular waste disposal Naples, June 17, 2025 – The University of Texas Southwestern Medical Center has awarded the Beth … The University of Texas Southwestern Medical Center has awarded the Beth Levine Prize in Autophagy Research to Andrea Ballabio , founder and former director of the Telethon Institute of Genetics and Medicine (TIGEM) in Pozzuoli, and Professor of Medical Genetics at the University of Naples Federico II. The award, which includes a $20,000 prize, honors his groundbreaking discoveries on the cellular mechanisms of autophagy and lysosomes, which are fundamental to understanding a … treating many rare genetic, neurodegenerative, and cancer-related diseases. The prize is named in memory of Beth Levine , an internationally renowned American scientist who passed away in 2020 and was known for discovering the first mammalian gene involved in autophagy: the process by which cells degrade and recycle damaged components to maintain health. Levine was a key figure in the scientific community and a source of great inspiration for Ballabio, with whom she shared no … event in Japan—also attended by Yoshinori Ohsumi (later awarded the 2016 Nobel Prize in Medicine for his pioneering work on autophagy)—that Levine suggested Ballabio co-found CASMA Therapeutics , a biotech company dedicated to developing innovative therapies by modulating this essential biological process. The award was presented on a particular
Andrea Ballabio: "The discovery is the 'magic moment' that any scientist is pursuing." | FEBS Network Skip to main content A network from FEBS RESEARCH Andrea Ballabio: "The discovery is the 'magic moment' that any scientist is pursuing." 'Meet' lysosome expert Andrea Ballabio, who will be awarded the 2025 Theodor Bücher medal from FEBS at the 49th FEBS Congress this summer. Feb 18, 2025 FEBS Communications Follow Like Liked by Gavin McStay Close Share this post Choose a social network to share with, or copy the URL to share elsewhere Share with... X … rks Following an MD degree at the University of Naples, Italy, and postdoctoral fellowship at the Institute of Genetics and Biophysics in Naples and at Guy’s hospital in London UK, Andrea Ballabio moved to the USA in 1989 where he was Assistant and then Associate Professor and Co-director of the Human Genome Center at the Department of Molecular and Human Genetics of Baylor College of Medicine in Houston, Texas. In 1994 he became the founding director of the Telethon Institut … Grants of the European Research Council (ERC) and in 2016 won the Louis-Jeantet prize for Medicine. Ballabio is also an Advisory Board Member of INGM Milan, IGBMC Strasbourg, Human Technopole Milan, and VIMM Padua. He is Co-Founder of CASMA Therapeutics and serves as scientific advisor in Next Generation Diagnostics and Avilar Therapeutics. He has been an EMBO member since 1998 and was a former member of the EMBO council. He has authored over 400 publications in international … iological Sciences from the University of Camerino. He then won the Feltrinelli Prize in 2021 and subsequently became member of the Accademia dei Lincei in Rome. What drew you to your research field? I wanted to become a paediatrician, so I joined medical school and then took a paediatric residency. While practicing as a paediatrician, I became more and more interested in understanding the basic mechanisms underlying genetic diseases. I was fascinated by the identification of
Casma Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Casma Therapeutics, Inc. Startups | Holding Company | 2017 | Massachusetts, United States | 10-50 | www.casmatx.com Startups | Holding Company | 2017 | Massachusetts, United States | 10-50 | www.casmatx.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Endocrinology and Metabolic Disease Neoplasms Small molecule drug Lysoso … l benefits for patients.” Casma plans to file an Investigational New Drug (IND) application with the US FDA for CSM-101 in the first half of 2026. About TRPML1 TRPML1 is a lysosomal ion channel that regulates critical aspects of lysosomal function, including lysosomal pH and the clearance of cellular waste. Dysfunction of TRPML1 leads to impaired degradation and accumulation of toxic substrates, contributing to the pathology of neurodegenerative and lysosomal storage diseases … nored many times for his work, including the Global Genes RARE Champion of Hope Award. He has an A.B. from Harvard College and an M.D. from Harvard Medical School. He completed his residency in Internal Medicine at Brigham and Women’s Hospital, his fellowship in Cardiology at MGH, and his postdoctoral studies at the Whitehead Institute at MIT. About Arbor Biotechnologies® Arbor Biotechnologies is a next-generation gene editing company focused on discovering and developing pot … for the next leg of the process, Mahmoud will be at the helm. Optinose plans to submit for a supplementary indication this month, which Mahmoud said could bring its drug from specialists to primary care providers. “It’s not a disease a lot of people know about, although it’s really common — 30 million people in the US. But as one patient once told me, it’s a Rodney Dangerfield disease: It doesn’t get any respect, because it rarely causes fatality, but it causes an awful lot o … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Casma Therapeutics Inc. - Page 1 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market … . has been awarded approximately $7.6 million in funding across two competitive grant programs from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support Casma’s lead program, CSM-101. Read More Neurology/psychiatric Casma Therapeutics identifies MCOLN1 activators Oct. 9, 2025 Casma Therapeutics Inc. has developed bicyclic heteroaromatic compounds acting as mucolipin-1 (MCOLN1; TRPML1) activators reported to be useful for the treatment of Duchenne muscular
Casma Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Casma Therapeutics, Inc. Startups | Holding Company | 2017 | Massachusetts, United States | 10-50 | www.casmatx.com Startups | Holding Company | 2017 | Massachusetts, United States | 10-50 | www.casmatx.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Endocrinology and Metabolic Disease Neoplasms Small molecule drug Lysoso … l benefits for patients.” Casma plans to file an Investigational New Drug (IND) application with the US FDA for CSM-101 in the first half of 2026. About TRPML1 TRPML1 is a lysosomal ion channel that regulates critical aspects of lysosomal function, including lysosomal pH and the clearance of cellular waste. Dysfunction of TRPML1 leads to impaired degradation and accumulation of toxic substrates, contributing to the pathology of neurodegenerative and lysosomal storage diseases … nored many times for his work, including the Global Genes RARE Champion of Hope Award. He has an A.B. from Harvard College and an M.D. from Harvard Medical School. He completed his residency in Internal Medicine at Brigham and Women’s Hospital, his fellowship in Cardiology at MGH, and his postdoctoral studies at the Whitehead Institute at MIT. About Arbor Biotechnologies® Arbor Biotechnologies is a next-generation gene editing company focused on discovering and developing pot … for the next leg of the process, Mahmoud will be at the helm. Optinose plans to submit for a supplementary indication this month, which Mahmoud said could bring its drug from specialists to primary care providers. “It’s not a disease a lot of people know about, although it’s really common — 30 million people in the US. But as one patient once told me, it’s a Rodney Dangerfield disease: It doesn’t get any respect, because it rarely causes fatality, but it causes an awful lot o … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Casma Therapeutics to Present at the Gordon Research Conference on Autophagy in Stress, Development, and Disease - Casma Therapeutics Casma Therapeutics to Present at the Gordon Research Conference on Autophagy in Stress, Development, and Disease - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics to Present at the Gordon Resear... Casma Therapeutics to Present at the Gordon Research Conference on A … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Platform & pipeline - Casma Therapeutics Platform & pipeline - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / Platform & pipeline Our approach TRPML1 PHLYT™ Videos Pipeline Platform & pipeline Our approach: Reprogramming autophagy At Casma, we are redefining degradation with our innovative methods. While traditional degradation techniques rely on the ubiquitin-proteasome pathway and often fall short for many crit … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
About us - Casma Therapeutics About us - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / About us About us Founded in 2018 and headquartered in Boston, MA, our team of experts in molecular biology and drug discovery is developing a technology that reprograms the autophagy pathway to degrade disease targets. Our mission To deliver novel therapeutics through a deeper understanding and engineering of autophagy. Our vision To aspire t … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Casma Therapeutics - Reprogramming autophagy to treat disease Casma Therapeutics - Reprogramming autophagy to treat disease Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us CASMA THERAPEUTICS A new approach to targeted degradation Reprogramming autophagy to treat disease The Science: Autophagy What is it? Autophagy is the removal of damaged components within the cell to maintain and improve health. How does it work? Autophagy creates autophagosomes that capture and deg … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
Casma Therapeutics Inc. Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Sign In Free Trial Sign In Free Trial Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Casma Therapeutics Inc. https://www.casmatx.com/ Industry Pharmaceuticals Specialty Pharmaceuticals Vaccines Biotechnology Drug Discovery Technologies See more in Biomedtracker Latest on Casma Therapeutics Inc. Already A Biomedtracker Subscriber? You have access to the full company record through your subscription. Go To Biomedtracker Twitter feed RSS feed RSS feed Podcast Spotify About About … st Spotify About About Us Opens in new window Meet the Team Editorial Standards Award-Winning Journalism Help Advertise Opens in new window Contact Us Evaluate Home Account My Account My View Email Preferences Start Free Trial Opens in new window Publications Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Terms and Conditions Opens in new window Privacy Policy Opens in new window
Casma Therapeutics - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science About Us Subscribe Fre
Our team - Casma Therapeutics Our team - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Our team Leadership positioned to operationalize autophagy therapies Explore team by: All Casmaniacs Board of Directors Founders & Scientific Advisors Leadership Andrea Ballabio Founder & Scientific Advisor Read Andrea's bio Andrea Ballabio Founder & Scientific Advisor Andrea Ballabio, M.D. Casma Founder Director & Founder, TIGEM Andrea Bal … national and international awards for research and culture, including the 2007 Award of the European Society of Human Genetics. In 2007, he received the “Knighthood of the Italian Republic” from the president of Italy. In 2016 he was the first in Italy to win the prestigious Louis-Jeantet Prize for Medicine for his contribution to understanding the molecular mechanisms controlling the function of lysosomes in health and disease. Andrea earned his medical degree at the Univer … sease. Andrea earned his medical degree at the University of Naples and did his residency in pediatrics. He completed his postdoctoral studies at Guy’s Hospital in London and the International Institute of Genetics and Biophysics in Naples, Italy. Beth Levine Founder (deceased) Read Beth's bio Beth Levine Founder (deceased) Beth Levine, M.D. Casma Founder Former Professor of Internal Medicine & Microbiology, University of Texas Southwestern Medical Center Beth Levin … tional Academy of Sciences. In 2014, she received the ASCI/Stanley J. Korsmeyer Award in recognition of fundamental contributions to our understanding of autophagy. Beth graduated from Brown University in 1981 and from Cornell University Medical College in 1986, followed by a residency in internal medicine. She completed a postdoctoral fellowship in infectious diseases and virology at Johns Hopkins University School of Medicine. Bob Tepper Director Read Bob's bio Bob Te … Protoc., and Science. For his work he received several awards, the Ernst-Reuter Award of the Free University Berlin (2005), the NCL Foundation Award (2016), and the Care for Rare Award of the LMU Munich Childrens’ Hospital (2017). Christian has also a PhD in Philosophy (Dr. phil.). Courteney Backstrom Benefits & Operations Courten
Casma Therapeutics Raises $46.0 M in Series C Funding - Casma Therapeutics Casma Therapeutics Raises $46.0 M in Series C Funding - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics Raises $46.0 M in Series C Fund... Casma Therapeutics Raises $46.0 M in Series C Funding November 15, 2022 CAMBRIDGE, Mass., November 15, 2022 – Casma Therapeutics , Inc., a biotechnology company engaging the autophagy sy … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics
News & media - Casma Therapeutics News & media - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home News & media News & media Filter by: Year Select One 2026 2025 2024 2023 2022 2021 2020 2019 2018 Type Select One News Publication Go Featured story News May 29, 2019 Casma Therapeutics Receives Grant from Michael J. Fox Foundation to Support Parkinson’s Drug Development CAMBRIDGE, Mass., May 29, 2019 — Casma Therapeutics, Inc., a biotechnol … w medicines, today announced receipt of a Therapeutic Pipeline Program research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support development of a novel class of drugs to treat Parkinson’s disease. […] News January 31, 2023 Casma Therapeutics Announces CEO Transition CAMBRIDGE, Mass., January 31, 2023 – Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced … ork to harness the potential of autophagy to design powerful new medicines. The award honors the most promising private biotechnology companies in the world. Casma has built a robust product engine to identify […] News May 29, 2019 Casma Therapeutics Receives Grant from Michael J. Fox Foundation to Support Parkinson’s Drug Development CAMBRIDGE, Mass., May 29, 2019 — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerfu … w medicines, today announced receipt of a Therapeutic Pipeline Program research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support development of a novel class of drugs to treat Parkinson’s disease. […] News April 12, 2019 Casma Therapeutics Named one of the Boston Business Journal’s Best Places to Work CAMBRIDGE, Mass. – April 12, 2019 – Casma Therapeutics, a biotechnology company harnessing the process of autophagy to design powerful … y announced that the company has been named a winner of the Best Places to Work award sponsored by the Boston Business Journal. The Boston Business Journal’s Best Places to Work awards are designed to honor […] Page 1 of 4 Posts pagination 1 2 3 4 About Casma Casma Therapeutics is developing novel cellular degradation approaches based on t
Casma Therapeutics Strengthens Leadership Team with Appointment of Chief Operating Officer, Vice President of People & Culture - Casma Therapeutics Casma Therapeutics Strengthens Leadership Team with Appointment of Chief Operating Officer, Vice President of People & Culture - Casma Therapeutics Our team Investors News & media Contact us The science: autophagy Platform & pipeline About us Careers & culture Our team Investors News & media Contact us Home / News & media / Casma Therapeutics Strengthens Leadership Team wit... Casma Therapeutics Strengthens L … ing from the Massachusetts Institute of Technology. He completed a postdoctoral fellowship at the Swiss Federal Institute of Technology in Zurich. “I loved working on Casma since its inception at Third Rock and am thrilled to stay with the team as we work to apply a wave of exciting new autophagy research to our drug discovery programs,” Gentile said. “This field has the potential to make a real difference for patients, and Casma is leading the way.” About Casma Therapeutics … & culture Investors News & media Our team The science: autophagy Fierce 15 list award in 2019 Privacy Policy Terms of use © 2026 Casma Therapeutics